Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
62.4% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
22
users have liked this narrative
6
users have commented on this narrative
50
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
30.9% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
31
users have liked this narrative
6
users have commented on this narrative
85
users have followed this narrative
New
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
19.2% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
11
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Sequans Communications
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Monarch And Calliope Projects Will Advance 5G IoT Amid Tensions
Key Takeaways Sequans expects significant revenue growth from Monarch and Calliope chip projects, accelerated by increased demand in telematics, security, and industrial markets. 5G advancements and cost management strategies, including the ACP acquisition and board refresh, target improved profitability and competitive positioning.
View narrative
US$7.50
FV
83.2% undervalued
intrinsic discount
22.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
7 days ago
author updated this narrative
R Systems International
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Cloud And AI Expansion Will Drive Global Digital Transformation
Key Takeaways Growth in cloud, AI, and automation, along with expanding partnerships and regional presence, is expected to drive higher revenue and improved margins. Focus on proprietary digital platforms and stable, long-term service lines should enhance margin expansion and predictability of cash flows.
View narrative
₹455.00
FV
5.4% undervalued
intrinsic discount
11.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
7 days ago
author updated this narrative
Technocraft Industries (India)
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Aurangabad Capacity And International Markets Will Drive Long-Term Expansion
Key Takeaways New plant capacity, process efficiencies, and value-added products are set to boost margins, operating leverage, and overall earnings stability. Global market expansion, infrastructure boom, and shifting manufacturing dynamics position the company for sustained export growth and increased international market share.
View narrative
₹4.33k
FV
29.0% undervalued
intrinsic discount
16.91%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Stelrad Group
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Tightening European Building Regulations Will Spark Energy Efficient Home Upgrades
Key Takeaways Regulatory shifts toward energy efficiency and decarbonization drive demand for Stelrad's innovative radiators, supporting revenue growth and increased margins through premium product focus. Investments in electric radiators, supply chain resilience, and sustainability enhance market positioning, drive margin improvement, and reduce regulatory risk for long-term stability.
View narrative
UK£1.89
FV
9.7% undervalued
intrinsic discount
3.11%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
21
users have followed this narrative
7 days ago
author updated this narrative
Empresa Distribuidora y Comercializadora Norte Sociedad Anónima
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Tariff Review And Grid Upgrades Will Drive Performance Amid Debt
Key Takeaways Secured regulatory certainty and planned tariff hikes will boost revenue stability, margins, and reduce future financial risks. Population growth and smart grid investments drive long-term demand, operational efficiency, and open opportunities in ancillary business segments.
View narrative
AR$2.80k
FV
25.9% undervalued
intrinsic discount
27.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
7 days ago
author updated this narrative
PDF Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Advanced Analytics And AI Will Transform Semiconductor Supply Chains
Key Takeaways Accelerating adoption of AI-driven analytics and partnerships with industry leaders are supporting recurring revenue growth and improved margins in semiconductor manufacturing solutions. Integration of recent acquisitions and platform expansion is unlocking new cross-selling, high-margin opportunities, positioning for long-term earnings and market share gains.
View narrative
US$31.75
FV
29.8% undervalued
intrinsic discount
19.62%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
7 days ago
author updated this narrative
Sumitomo Heavy Industries
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Restructuring And Clean Energy Focus Will Unlock Future Value
Key Takeaways Operational restructuring and focus on high-margin products, services, and digital transformation are aimed at driving profitability and recurring revenues. Strategic investments in automation, healthcare innovation, and clean energy position the company for long-term global growth and reduced domestic market reliance.
View narrative
JP¥3.34k
FV
0.4% overvalued
intrinsic discount
1.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Milbon
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Digital Expansion And Global Reach Will Define Future Leadership
Key Takeaways Expansion in global markets and emphasis on premium, innovative beauty products are accelerating revenue growth and strengthening brand differentiation. Investments in digital platforms, salon training, and sustainable product development are boosting customer retention, margins, and long-term earnings potential.
View narrative
JP¥2.95k
FV
13.2% undervalued
intrinsic discount
5.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Mersana Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Emi-Le Trials And TNBC Focus Will Deliver Promise With Risk
Key Takeaways Emi-Le's promising clinical trial results and focus on unmet needs in breast cancer could drive significant future revenue and market share gains. Collaborations with major pharmaceutical companies may boost Mersana’s platform capabilities and diversify its pipeline, enhancing future revenue streams.
View narrative
US$123.29
FV
94.6% undervalued
intrinsic discount
7.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
Value any company in seconds
Popular companies